Finished Dosage Form (FDF) export of Laninamivir obtained from Indian Custom Trade Statistics

Laninamivir

ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow

media
1 DATA COMPILATION #PharmaFlow

GLOBAL SALES INFORMATION

3 Annual Reports

globalSalesInformation
3 Annual Reports

MARKET PLACE

1 APIs

marketPlace
1 APIs

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

345

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 203120-17-6, R-125489, (2r,3r,4s)-3-acetamido-4-(diaminomethylideneamino)-2-[(1r,2r)-2,3-dihydroxy-1-methoxypropyl]-3,4-dihydro-2h-pyran-6-carboxylic acid, B408iw3gl5, Laninamivir (inn), D-glycero-d-galacto-non-2-enonic acid, 5-(acetylamino)-4-[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy-7-o-methyl-

Molecular Formula

C₁₃H₂₂N₄O₇

Molecular Weight

346.34 g/mol

InChI Key

QNRRHYPPQFELSF-CNYIRLTGSA-N

FDA UNII

B408IW3GL5

Laninamivir has been used in trials studying the treatment of Influenza.

1 2D Structure

Laninamivir

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-2,3-dihydroxy-1-methoxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid

2.1.2 InChI

InChI=1S/C13H22N4O7/c1-5(19)16-9-6(17-13(14)15)3-8(12(21)22)24-11(9)10(23-2)7(20)4-18/h3,6-7,9-11,18,20H,4H2,1-2H3,(H,16,19)(H,21,22)(H4,14,15,17)/t6-,7+,9+,10+,11+/m0/s1

2.1.3 InChI Key

QNRRHYPPQFELSF-CNYIRLTGSA-N

2.1.4 Canonical SMILES

CC(=O)NC1C(C=C(OC1C(C(CO)O)OC)C(=O)O)N=C(N)N

2.1.5 Isomeric SMILES

CC(=O)N[C@@H]1[C@H](C=C(O[C@H]1[C@@H]([C@@H](CO)O)OC)C(=O)O)N=C(N)N

2.2 Other Identifiers

2.2.1 UNII

B408IW3GL5

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 5-(acetylamino)-4-((aminoiminomethyl)amino)-2,6-anhydro-3,4,5-trideoxy-7-o-methyl-d-glycero-d-galacto-non-2-enonic Acid

2. Laninamivir Octanoate

3. Laninamivir Octanoate Hydrate

4. Laninamivir Octanoate Monohydrate

5. Laninamivir Trifluoroacetate

6. R 125489

7. R-125489

8. R125489

2.3.2 Depositor-Supplied Synonyms

1. 203120-17-6

2. R-125489

3. (2r,3r,4s)-3-acetamido-4-(diaminomethylideneamino)-2-[(1r,2r)-2,3-dihydroxy-1-methoxypropyl]-3,4-dihydro-2h-pyran-6-carboxylic Acid

4. B408iw3gl5

5. Laninamivir (inn)

6. D-glycero-d-galacto-non-2-enonic Acid, 5-(acetylamino)-4-[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy-7-o-methyl-

7. Laninamivir [inn]

8. (2r,3r,4s)-3-acetamido-2-((1r,2r)-2,3-dihydroxy-1-methoxypropyl)-4-guanidino-3,4-dihydro-2h-pyran-6-carboxylic Acid

9. (4s,5r,6r)-5-acetamido-4-carbamimidamido-6-((1r,2r)-3-hydroxy-2-methoxypropyl)-5,6-dihydro-4h-pyran-2-carboxylic Acid

10. 5-(acetylamino)-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-7-o-methyl-d-glycero-d-galacto-non-2-enonic Acid

11. Laninamivir [inn:jan]

12. Laninamivir (cs-8958)

13. Unii-b408iw3gl5

14. Lani

15. Laninamivir [mi]

16. Laninamivir [mart.]

17. Laninamivir [who-dd]

18. Chembl466246

19. Schembl12284832

20. Dtxsid60942457

21. Chebi:177801

22. Bcpp000190

23. Glxc-15033

24. Bcp27633

25. Ex-a4019

26. Zinc3985629

27. Bdbm50009296

28. Akos015850995

29. Akos032947260

30. Bcp9000836

31. Db12791

32. (2r,3r,4s)-3-acetamido-2-[(1r,2r)-2,3-dihydroxy-1-methoxy-propyl]-4-guanidino-3,4-dihydro-2h-pyran-6-carboxylic Acid

33. (4s,5r,6r)-5-acetamido-4-guanidino-6-((1r,2r)-2,3-dihydroxy-1-methoxypropyl)-5,6-dihydro-4h-pyran-2-carboxylic Acid

34. Ac-36457

35. Hy-14818

36. Cs-0003575

37. C21557

38. D09410

39. 120l176

40. A814430

41. Q6487096

42. R 125489r 125489

43. (4s,5r,6r)-5-acetamido-4-guanidino-6- ((1r,2r)-2,3-dihydroxy-1-methoxypropyl)-5,6-dihydro-4h-pyran-2-carboxylic Acid

44. 5-(acetylamino)-4-[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy-7-o-methyl-d-glycero-d-galacto-non-2-enonic Acid

45. 5-acetylamino-4-(diaminomethyl-amino)-6-(2,3-dihydroxy-1-methoxy-propyl)-5,6-dihydro-4h-pyran-2-carboxylic Acid

2.4 Create Date

2005-08-01

3 Chemical and Physical Properties

Molecular Formula	C₁₃H₂₂N₄O₇
Molecular Weight	346.34 g/mol
XLogP3	-3.2
Hydrogen Bond Donor Count	6
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	7
Exact Mass	346.14884905 g/mol
Monoisotopic Mass	346.14884905 g/mol
Topological Polar Surface Area	190 Å²
Heavy Atom Count	24
Formal Charge	0
Complexity	532
Isotope Atom Count	0
Defined Atom Stereocenter Count	5
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Antiviral Agents

Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)

4.2 ATC Code

J - Antiinfectives for systemic use

J05 - Antivirals for systemic use

J05A - Direct acting antivirals

J05AH - Neuraminidase inhibitors

J05AH04 - Laninamivir

Digital Content

Create Content with PharmaCompass, ask us